Dupixent^® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US FDA has accepted for Priority Review the supplemental Biologics License Application for Dupixent® as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled CRSwNP.